Skip to content
OpenCapital
Get started

Ardelyx ARDX United States — Total revenues

Similar metrics at other companies

Aurinia Pharmaceuticals logo
AUPHU.S. — Revenue
$65.96M+25.6%
Schrodinger logo
SDGRUnited States — Total revenues
$31.41M+5.9%
CareDx logo
CDNAUnited States — Total Revenue
$113.65M+42.3%
Incyte logo
INCYUnited States — Total revenues
$1.17B+19.3%
IAR
IARTUnited States — Total Revenues
$289.38M+2.5%
Azenta logo
AZTAUnited States — Total Revenue
$83.02M-7.7%

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+79.5%
Enterprise value$1.71B+74.8%
P/S3.6×+1.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%—
Net margin-13.6%—
FCF margin-40.9%—

Returns & leverage

See full
Return on equity-39.5%—
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Ardelyx’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's united states — total revenues.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's united states — total revenues?
Ardelyx (ARDX) reported united states — total revenues of $94.45M in Q4 2025.
How has Ardelyx's united states — total revenues changed year-over-year?
Ardelyx's united states — total revenues increased by 18.4% year-over-year, from $79.8M to $94.45M.
What does united states — total revenues mean?
This metric represents the total gross income generated from the sale of pharmaceutical products and licensing arrangements within the United States market. It serves as a primary indicator of the company's commercial success, market penetration, and the adoption rate of its therapeutic portfolio in the domestic healthcare sector. Growth in this figure reflects the successful execution of commercialization strategies and the scaling of product demand.